Roche arthritis drug reduces Covid-19 deaths in trial on hospitalised patients

COVID-19 | Roche's arthritis drug tocilizumab cuts the risk of death among patients hospitalised with severe Covid-19, also shortening the time to recovery and reducing the need for mechanical ventilation, results of a large trial showed on Thursday.

The findings - from the Recovery trial, which has been testing a range of potential treatments for Covid-19 since March 2020 - should help clear up confusion about the potential benefits of tocilizumab for Covid-19 patients after a slew of recent mixed trial results...